131 related articles for article (PubMed ID: 17662552)
1. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth.
Petersen PJ; Jones CH; Bradford PA
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):347-9. PubMed ID: 17662552
[TBL] [Abstract][Full Text] [Related]
2. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.
Petersen PJ; Labthavikul P; Jones CH; Bradford PA
J Antimicrob Chemother; 2006 Mar; 57(3):573-6. PubMed ID: 16431863
[TBL] [Abstract][Full Text] [Related]
5. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.
Pachón-Ibáñez ME; Jiménez-Mejías ME; Pichardo C; Llanos AC; Pachón J
Antimicrob Agents Chemother; 2004 Nov; 48(11):4479-81. PubMed ID: 15504889
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
Vouillamoz J; Moreillon P; Giddey M; Entenza JM
J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
[TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
[TBL] [Abstract][Full Text] [Related]
9. In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline.
Alou L; Giménez MJ; Cafini F; Aguilar L; Sevillano D; González N; Torrico M; Prieto J; García-Rey C; García-Escribano N
J Antimicrob Chemother; 2009 Dec; 64(6):1230-3. PubMed ID: 19837715
[TBL] [Abstract][Full Text] [Related]
10. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
11. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii.
Bantar C; Schell C; Posse G; Limansky A; Ballerini V; Mobilia L
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):309-14. PubMed ID: 18375084
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
Gales AC; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
[TBL] [Abstract][Full Text] [Related]
14. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.
Rose WE; Poppens PT
J Antimicrob Chemother; 2009 Mar; 63(3):485-8. PubMed ID: 19109338
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.
Bradford PA; Petersen PJ; Young M; Jones CH; Tischler M; O'Connell J
Antimicrob Agents Chemother; 2005 Sep; 49(9):3903-9. PubMed ID: 16127069
[TBL] [Abstract][Full Text] [Related]
16. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.
Hope R; Warner M; Mushtaq S; Ward ME; Parsons T; Livermore DM
J Antimicrob Chemother; 2005 Dec; 56(6):1042-6. PubMed ID: 16286361
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
Seifert H; Dowzicky MJ
Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: a review of a new glycylcycline antibiotic.
Scheinfeld N
J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
20. Influence of polysorbate-80 when determining the tigecycline MIC by the reference method.
Jones RN; Knapp CC; Dowzicky MJ
Diagn Microbiol Infect Dis; 2007 May; 58(1):145-6. PubMed ID: 17368804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
